Amio-Aqueous lacked the hypotensive and cardiotoxic properties of Cordarone IV, showing no effect on contractility at 10 mg/kg compared to a 29% decrease with Cordarone (P<0.001).
Does an aqueous formulation of intravenous amiodarone reduce toxicity and hypotension compared to standard intravenous amiodarone in Sprague-Dawley rats?
A new aqueous formulation of intravenous amiodarone eliminates the hypotensive and negative inotropic effects seen with the standard formulation in a rat model.
Absolute Event Rate: 0% vs 29%
p-value: p=<0.001
Hypotension is the most frequent adverse event reported with intravenous amiodarone (Cordarone IV). The hypotension has been attributed to the vasoactive solvents of the formulation, polysorbate 80 and benzyl alcohol, both known to exhibit negative inotropy and hypotensive effect. A new aqueous formulation of intravenous amiodarone (Amio-Aqueous) does not contain vasoactive excipients and may be less toxic and cause less hypotension than Cordarone IV. This hypothesis was tested in a series of animal studies with direct comparison of Amio-Aqueous and Cordarone IV. All studies were performed on Sprague-Dawley rats. The acute toxicology study showed that both LD50 and LD100 were 30% greater for Amio-Aqueous than for Cordarone. At the dose at which all animals expired on Cordarone, 50% of animals were still alive on Amio-Aqueous. The study on myocardial contractility showed that Amio-Aqueous was a far less negative inotropic than Cordarone IV (P < 0.001). Amio Aqueous did not have an effect on contractility at 5- and 10-mg/kg dose levels while Cordarone resulted in a 25% (P < 0.01) and 29% (P < 0.002) decrease, respectively. The study on arterial blood pressure showed that Cordarone caused a significant decrease in blood pressure at each of the 3, 5, 10, and 20 mg/kg doses (P < 0.05 to P < 0.001) while Amio-Aqueous did not. The study on the antiarrhythmic effects showed comparable efficacy for both formulations. In conclusion, Cordarone IV was more toxic and caused significant hypotension and negative inotropy while Amio-Aqueous lacked the hypotensive and cardiotoxic properties of Cordarone. Therefore, Amio-Aqueous is a safer alternative than the standard formulation.
Somberg et al. (Sat,) reported a other. Amio-Aqueous vs. Cordarone IV was evaluated on Decrease in myocardial contractility at 10 mg/kg dose (p=<0.001). Amio-Aqueous lacked the hypotensive and cardiotoxic properties of Cordarone IV, showing no effect on contractility at 10 mg/kg compared to a 29% decrease with Cordarone (P<0.001).